The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global intermittent catheters market size reached US$ 2.36 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 3.6 Billion by 2027, exhibiting a growth rate (CAGR) of 7.10% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Intermittent catheterization is a procedure of inserting and removing a catheter to drain urine from a bladder. It is an effective bladder management strategy for patients with incomplete bladder emptying due to idiopathic or neurogenic detrusor overactivity (NDO) dysfunction, inflammation, neurological conditions, pharmacological agents, and physical bladder obstruction. It is easy to use and convenient while preventing a distended bladder or a urinary tract infection (UTI). Besides this, as it avoids leaking, blockage, and bladder spasms, the demand for intermittent catheters are increasing across the globe.
At present, there is a rise in the number of patients suffering from urinary tract infections (UTIs) and blockages in the urethra around the world. This, along with the growing incidences of tumors in the urinary tract or reproductive organs, represents one of the key factors driving the market. Moreover, the rising prevalence of urological disorders, such as cystitis, benign prostatic hyperplasia, and kidney stones, among the masses is offering lucrative growth opportunities to industry investors. Besides this, there is an increase in the demand for intermittent catheters in various medical conditions, such as spinal cord injury, multiple sclerosis, or dementia. This, coupled with the burgeoning healthcare industry, is contributing to the growth of the market. In addition, key market players are extensively investing in research and development (R&D) activities to introduce coated urine catheters with temperature monitoring for enhanced protection against secondary infections. They are also launching platforms for providing online counseling and guidance to patients who cannot visit healthcare facilities for treatment. Apart from this, the escalating demand for novel catheters, such as hydrophilic antimicrobial intermittent catheters, is bolstering the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global intermittent catheters market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, indication, category and end user.
Breakup by Product:
Breakup by Indication:
Breakup by Category:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being B. Braun Melsungen AG, Becton Dickinson and Company, Coloplast A/S, Cure Medical LLC (Convatec Group plc), Hollister Incorporated, Hunter Urology, Medical Technologies of Georgia Inc., Pennine Healthcare Ltd., Teleflex Inc and Wellspect Limited (Dentsply Sirona).
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Indication, Category, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||B. Braun Melsungen AG, Becton Dickinson and Company, Coloplast A/S, Cure Medical LLC (Convatec Group plc), Hollister Incorporated, Hunter Urology, Medical Technologies of Georgia Inc., Pennine Healthcare Ltd., Teleflex Inc and Wellspect Limited (Dentsply Sirona).|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at